« HIV-Specific CD4 T Cells Harbor the Majority of Latent Virus: Implications for Therapeutic Vaccines | Main | Assessing the Role of Virus-Specific CD4 T Cells in Controlling SIV »

TrackBack

TrackBack URL for this entry:
http://www.typepad.com/services/trackback/6a00d8341d071153ef015391faf5e8970b

Listed below are links to weblogs that reference Lost In Translation: Crazy Claims About MVA-B HIV Vaccine Candidate :

Comments

Mariano Esteban, Professor, Centro Nacional de Biotecnologia, CSIC

I would would like respond to Michael Palm posted comment entitled "Lost in Translation: Crazy Claims About MVA-B HIV Vaccine.

1. In view of the wrong interpretation that had appeared on the news about CSIC press release on the vaccine MVA-B, a statement has been forwarded by CSIC to international press to clarify the findings of the phase I clinical trial in Spain with MVA-B, given below:

CORRECTIONS ON THE SPANISH HIV VACCINE

While news have appeared wrongly implying 90% protective efficacy of the Spanish HIV vaccine, with moral implications to those suffering the virus infection, the phase I clinical trial performed in Spain and results published in two scientific journals, only proved that the vaccine induced prolong immune responses to HIV antigens in high per cent of the healthy volunteers not exposed to HIV. At present, it is not known if the vaccine can protect against HIV.

2. I regret that statements I made in the press release, with the best intention to help explain the results, were unfortunate

3. Your comment that "there is no assesment of whether the CD8 T cell responses induced by MVA-B can actually kill HIV-infected cells, a parameter that has emerged as critically important for T cell vaccines" was shown before in our previous publication (Climent N et al. 2011. PLoS ONE 6, 5). In the Abstract of the article it is described "MVA-B infected monocyte-derived dendritic cells (MDDC) co-cultured with autologous T lymphocytes induced a highly functional HIV-specific CD8+ T cell responses including proliferation, secretion of IFN-gamma, IL-2, TNF-alpha, MIP-1B, MIP-1a, RANTES and IL-6, and strong cytotoxic activity against autologous HIV-infected CD4+ T lymphocytes"

4. As we have discussed in our JVI publication, MVA-B appears to be an immunogen that is as good or even better than other MVA-based HIV vaccines and in the Vaccine publication "MVA-B deserves to be considered as a potential HIV/AIDS vaccine candidate to be used alone or in prime-boost combination with other immunogens in future trials". Clearly, there are other HIV vaccine candidates that are more potent, particularly when combined with other immunogens.

5. Our contribution in the pursuit of an HIV vaccine is one among many efforts worlwide to develop an effective vaccine, thus far only achieved, in part, by the RV-144 trial in Thailand.

I appreciate your critical comments and would like to see if you can post these clarifications.

Verify your Comment

Previewing your Comment

This is only a preview. Your comment has not yet been posted.

Working...
Your comment could not be posted. Error type:
Your comment has been saved. Comments are moderated and will not appear until approved by the author. Post another comment

The letters and numbers you entered did not match the image. Please try again.

As a final step before posting your comment, enter the letters and numbers you see in the image below. This prevents automated programs from posting comments.

Having trouble reading this image? View an alternate.

Working...

Post a comment

Comments are moderated, and will not appear until the author has approved them.

AllTrials logo

Other Accounts

Enter your email address:

Delivered by FeedBurner

Search this blog


My Photo

December 2014

Sun Mon Tue Wed Thu Fri Sat
  1 2 3 4 5 6
7 8 9 10 11 12 13
14 15 16 17 18 19 20
21 22 23 24 25 26 27
28 29 30 31      
Blog powered by Typepad
Member since 09/2005